430 related articles for article (PubMed ID: 20416867)
1. Preventing ovarian hyperstimulation syndrome: guidance for the clinician.
Humaidan P; Quartarolo J; Papanikolaou EG
Fertil Steril; 2010 Jul; 94(2):389-400. PubMed ID: 20416867
[TBL] [Abstract][Full Text] [Related]
2. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
Griesinger G
Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
[TBL] [Abstract][Full Text] [Related]
4. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome.
Mathur R; Kailasam C; Jenkins J
Hum Fertil (Camb); 2007 Jun; 10(2):75-85. PubMed ID: 17564886
[TBL] [Abstract][Full Text] [Related]
5. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
6. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.
Kol S; Itskovitz-Eldor J
Semin Reprod Med; 2010 Nov; 28(6):500-5. PubMed ID: 21082509
[TBL] [Abstract][Full Text] [Related]
8. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
9. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
10. Ovarian stimulation in patients in risk of OHSS.
Soave I; Marci R
Minerva Ginecol; 2014 Apr; 66(2):165-78. PubMed ID: 24848075
[TBL] [Abstract][Full Text] [Related]
11. Identification of the high-risk patient for ovarian hyperstimulation syndrome.
Papanikolaou EG; Humaidan P; Polyzos NP; Tarlatzis B
Semin Reprod Med; 2010 Nov; 28(6):458-62. PubMed ID: 21082503
[TBL] [Abstract][Full Text] [Related]
12. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose.
Kashyap S; Parker K; Cedars MI; Rosenwaks Z
Semin Reprod Med; 2010 Nov; 28(6):475-85. PubMed ID: 21082506
[TBL] [Abstract][Full Text] [Related]
13. Agonist and antagonist coast.
Aboulghar M
Fertil Steril; 2012 Mar; 97(3):523-6. PubMed ID: 22265033
[TBL] [Abstract][Full Text] [Related]
14. Withholding gonadotropins until human chorionic gonadotropin administration.
Abdallah R; Kligman I; Davis O; Rosenwaks Z
Semin Reprod Med; 2010 Nov; 28(6):486-92. PubMed ID: 21082507
[TBL] [Abstract][Full Text] [Related]
15. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol.
Fatemi HM; Popovic-Todorovic B; Humaidan P; Kol S; Banker M; Devroey P; García-Velasco JA
Fertil Steril; 2014 Apr; 101(4):1008-11. PubMed ID: 24534283
[TBL] [Abstract][Full Text] [Related]
16. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
Fatemi HM; Garcia-Velasco J
Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
[TBL] [Abstract][Full Text] [Related]
17. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.
Fernández-Sánchez M; Fatemi H; García-Velasco JA; Heiser PW; Daftary GS; Mannaerts B
Gynecol Endocrinol; 2023 Dec; 39(1):2205952. PubMed ID: 37156263
[TBL] [Abstract][Full Text] [Related]
18. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: a prospective, clinical feasibility study.
Griesinger G; Berndt H; Schultz L; Schultze-Mosgau A; Diedrich K; von Otte S
Reprod Biomed Online; 2011 Feb; 22(2):133-9. PubMed ID: 21227753
[TBL] [Abstract][Full Text] [Related]
19. Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos.
D'Angelo A
Semin Reprod Med; 2010 Nov; 28(6):513-8. PubMed ID: 21082511
[TBL] [Abstract][Full Text] [Related]
20. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.
Herrero L; Pareja S; Losada C; Cobo AC; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Mar; 95(3):1137-40. PubMed ID: 21047635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
